Laboratorios Farmaceuticos Rovi S.A. | Large-cap | Healthcare
€53.75
1.22%
| Laboratorios Stock Comparison:
Laboratorios vs Almirall S.ALaboratorios vs Faes Farma S.ALaboratorios vs Laboratorio ReigLaboratorios vs Labiana Health S.ALaboratorios vs Grifols, S.ALaboratorios vs IBEX 35 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 154.9M
Gross Profit 90.4M 58.36%
Operating Income 23.1M 14.91%
Net Income 18.1M 11.67%
EPS (Diluted) €0.35

Balance Sheet Metrics

Total Assets 814.0M
Total Liabilities 214.5M
Shareholders Equity 599.5M
Debt to Equity 0.36

Cash Flow Metrics

Operating Cash Flow 54.8M
Free Cash Flow 10.6M

Revenue & Profitability Trend

Laboratorios Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i763.7M829.5M817.7M648.7M420.0M
Cost of Goods Sold i285.4M337.2M298.1M263.9M178.7M
Gross Profit i478.3M492.3M519.6M384.8M241.3M
Gross Margin % i62.6%59.3%63.5%59.3%57.5%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i39.4M38.0M32.8M12.7M11.4M
Other Operating Expenses i95.7M85.2M100.2M80.0M59.3M
Total Operating Expenses i135.1M123.2M133.0M92.7M70.7M
Operating Income i179.5M220.3M255.8M181.5M77.4M
Operating Margin % i23.5%26.6%31.3%28.0%18.4%
Non-Operating Items
Interest Income i26.0K7.0K6.0K68.0K4.0K
Interest Expense i2.0M667.0K606.0K669.0K806.0K
Other Non-Operating Income-----
Pre-tax Income i177.7M220.4M258.0M182.6M72.6M
Income Tax i40.8M50.1M58.3M29.6M11.5M
Effective Tax Rate % i23.0%22.7%22.6%16.2%15.9%
Net Income i136.9M170.3M199.7M153.1M61.1M
Net Margin % i17.9%20.5%24.4%23.6%14.5%
Key Metrics
EBITDA i207.6M245.6M279.6M202.7M96.8M
EPS (Basic) i€2.68€3.29€3.73€2.76€1.10
EPS (Diluted) i€2.68€3.29€3.73€2.76€1.10
Basic Shares Outstanding i5114949851820146534660005540400055386000
Diluted Shares Outstanding i5114949851820146534660005540400055386000

Income Statement Trend

Laboratorios Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i27.2M25.3M124.9M99.0M53.2M
Short-term Investments i227.0K----
Accounts Receivable i129.5M143.3M180.0M150.2M76.4M
Inventory i330.0M338.0M311.9M245.5M227.2M
Other Current Assets2.7M----
Total Current Assets i489.6M509.3M623.1M506.4M364.6M
Non-Current Assets
Property, Plant & Equipment i116.6M120.1M97.3M84.1M77.0M
Goodwill i34.0M33.9M35.7M38.6M41.4M
Intangible Assets i34.0M33.9M35.7M38.6M41.4M
Long-term Investments-----
Other Non-Current Assets65.0K----
Total Non-Current Assets i342.4M290.6M255.6M226.3M209.9M
Total Assets i832.0M799.9M878.7M732.7M574.4M
Liabilities
Current Liabilities
Accounts Payable i86.9M107.6M123.9M97.4M63.5M
Short-term Debt i23.7M13.2M12.7M6.4M5.1M
Current Portion of Long-term Debt-----
Other Current Liabilities5.2M----
Total Current Liabilities i156.7M199.8M293.9M190.4M122.9M
Non-Current Liabilities
Long-term Debt i90.7M52.2M59.4M66.7M68.4M
Deferred Tax Liabilities i366.0K1.5M677.0K776.0K929.0K
Other Non-Current Liabilities2.7M----
Total Non-Current Liabilities i93.8M56.5M63.4M71.3M77.8M
Total Liabilities i250.5M256.4M357.3M261.7M200.7M
Equity
Common Stock i3.1M3.2M3.2M3.4M3.4M
Retained Earnings i486.2M555.5M456.0M445.4M302.2M
Treasury Stock i5.5M107.7M27.6M66.1M20.2M
Other Equity-----
Total Shareholders Equity i581.5M543.5M521.4M471.0M373.7M
Key Metrics
Total Debt i114.4M65.4M72.1M73.1M73.5M
Working Capital i333.0M309.5M329.2M316.0M241.7M

Balance Sheet Composition

Laboratorios Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i177.7M220.4M258.0M182.6M72.6M
Depreciation & Amortization i-----
Stock-Based Compensation i--01.4M0
Working Capital Changes i25.3M-10.5M-98.6M-99.4M-62.9M
Operating Cash Flow i203.9M208.2M155.5M79.0M8.6M
Investing Activities
Capital Expenditures i-59.1M-53.4M-50.6M-40.2M-39.3M
Acquisitions i-19.1M1.2M0--
Investment Purchases i-0-5.9M0-
Investment Sales i80.0K88.0K20.0K0-
Investing Cash Flow i-78.1M-52.1M-56.5M-40.2M-39.3M
Financing Activities
Share Repurchases i-89.7M-133.9M-177.0M-78.8M-37.3M
Dividends Paid i-56.5M-69.0M-51.0M-21.1M-9.7M
Debt Issuance i97.0M734.0K1.4M1.3M1.4M
Debt Repayment i-51.7M-13.7M-6.8M-6.2M-13.2M
Financing Cash Flow i-53.6M-160.5M-154.2M-62.4M-21.2M
Free Cash Flow i76.1M58.1M186.2M108.5M7.2M
Net Change in Cash i72.2M-4.4M-55.2M-23.6M-51.9M

Cash Flow Trend

Laboratorios Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 20.56
Forward P/E 19.65
Price to Book 4.83
Price to Sales 3.64
PEG Ratio 19.65

Profitability Ratios

Profit Margin 17.66%
Operating Margin 17.14%
Return on Equity 25.01%
Return on Assets 12.50%

Financial Health

Current Ratio 2.77
Debt to Equity 22.50
Beta 0.44

Per Share Data

EPS (TTM) €2.59
Book Value per Share €11.02
Revenue per Share €14.65

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
rovi2.7B20.564.8325.01%17.66%22.50
Almirall S.A 2.2B102.601.511.45%2.02%26.47
Faes Farma S.A 1.3B12.411.8014.83%19.37%11.48
Laboratorio Reig 240.1M42.141.103.03%1.89%31.04
Labiana Health S.A 27.9M-5.806.92%0.38%1,378.08
Grifols, S.A 7.8B29.191.694.99%4.00%126.87

Financial data is updated regularly. All figures are in the company's reporting currency.